Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Vaxcyte
ISIN US92243G1085
|WKN A2P6R6
Market cap (in EUR)
4,965 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
Advertisement
Capital at risk. Execution-only service.
Overview
Description
Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 4,965 m |
| EPS, EUR | -4.46 |
| P/B ratio | 2.0 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | - |
| Net income, EUR | -429 m |
| Profit margin | - |
What ETF is Vaxcyte in?
There are 37 ETFs which contain Vaxcyte. All of these ETFs are listed in the table below. The ETF with the largest weighting of Vaxcyte is the Harbor Health Care UCITS ETF Accumulating.
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.